Vytorin Price Will Be Key To Impact In Cholesterol Market, AstraZeneca Says
Executive Summary
The uptake of Vytorin (ezetimibe/simvastatin) will depend on the pricing strategy adopted by Merck and Schering-Plough, AstraZeneca CEO Tom McKillop predicted during a July 22 earnings call
You may also be interested in...
Merck/Schering’s Vytorin Clears FDA: Price Is 22% Discount To Lipitor
Merck/Schering-Plough's cholesterol-lowering agent Vytorin will carry a wholesale acquisition cost that is a 22% discount to the three highest doses of Pfizer's Lipitor
Merck/Schering’s Vytorin Clears FDA: Price Is 22% Discount To Lipitor
Merck/Schering-Plough's cholesterol-lowering agent Vytorin will carry a wholesale acquisition cost that is a 22% discount to the three highest doses of Pfizer's Lipitor
Merck/Schering Vytorin Launch Could Be Aided By New Cholesterol Guidelines
Revised cholesterol treatment guidelines could result in increased use of combination lipid-lowering therapies as Merck/Schering-Plough's Vytorin enters the market